253 related articles for article (PubMed ID: 37271776)
21. Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis.
Barroso-Sousa R; Barry WT; Garrido-Castro AC; Hodi FS; Min L; Krop IE; Tolaney SM
JAMA Oncol; 2018 Feb; 4(2):173-182. PubMed ID: 28973656
[TBL] [Abstract][Full Text] [Related]
22. Safety and Efficacy Outcomes in Immune Checkpoint Inhibitor-Treated Patients With Metastatic Urothelial Carcinoma Requiring Treatment Interruption or Discontinuation Due to Immune-Related Adverse Events.
Nizam A; Rader RK; Tzeng A; Wei W; Sheng IY; Martin A; Wee CE; Gilligan TD; Gupta S; Ornstein MC
Clin Genitourin Cancer; 2024 Apr; 22(2):368-379. PubMed ID: 38245437
[TBL] [Abstract][Full Text] [Related]
23. Prevalence of immune-related adverse events and anti-tumor efficacy in advanced/metastatic urothelial carcinoma following immune-checkpoint inhibitor treatment.
Morales-Barrera R; Villacampa G; Vidal N; Figols M; Giner J; Bonfill T; Suárez C; Díaz N; Mateo J; González M; Domenech M; Puente J; Carles J
Clin Transl Oncol; 2023 Dec; 25(12):3556-3564. PubMed ID: 37217634
[TBL] [Abstract][Full Text] [Related]
24. Correlation Between Immune-Related Adverse Events and Prognosis in Hepatocellular Carcinoma Patients Treated With Immune Checkpoint Inhibitors.
Xu S; Lai R; Zhao Q; Zhao P; Zhao R; Guo Z
Front Immunol; 2021; 12():794099. PubMed ID: 34950153
[TBL] [Abstract][Full Text] [Related]
25. The determinants of very severe immune-related adverse events associated with immune checkpoint inhibitors: A prospective study of the French REISAMIC registry.
Ruste V; Goldschmidt V; Laparra A; Messayke S; Danlos FX; Romano-Martin P; Champiat S; Voisin AL; Baldini C; Massard C; Laghouati S; Marabelle A; Lambotte O; Michot JM
Eur J Cancer; 2021 Nov; 158():217-224. PubMed ID: 34627664
[TBL] [Abstract][Full Text] [Related]
26. First-line immune-checkpoint inhibitor combination therapy for chemotherapy-eligible patients with metastatic urothelial carcinoma: A systematic review and meta-analysis.
Mori K; Pradere B; Moschini M; Mostafaei H; Laukhtina E; Schuettfort VM; Sari Motlagh R; Soria F; Teoh JYC; Egawa S; Powles T; Shariat SF;
Eur J Cancer; 2021 Jul; 151():35-48. PubMed ID: 33962359
[TBL] [Abstract][Full Text] [Related]
27. Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitors.
Ma VT; Su CT; Hu M; Taylor JMG; Daignault-Newton S; Kellezi O; Dahl MN; Shah MA; Erickson S; Lora J; Hamasha R; Ali A; Yancey S; Kiros L; Balicki HM; Winfield DC; Green MD; Alva AS
Urol Oncol; 2021 Jul; 39(7):437.e1-437.e9. PubMed ID: 33495117
[TBL] [Abstract][Full Text] [Related]
28. Long-Term Toxicities of Immune Checkpoint Inhibitor (ICI) in Melanoma Patients.
Tong J; Kartolo A; Yeung C; Hopman W; Baetz T
Curr Oncol; 2022 Oct; 29(10):7953-7963. PubMed ID: 36290906
[TBL] [Abstract][Full Text] [Related]
29. Immune-Related Adverse Events and Clinical Outcomes in Advanced Urothelial Cancer Patients Treated With Immune Checkpoint Inhibitors.
Sanda GE; Shabto JM; Goyal S; Liu Y; Martini DJ; Nazha B; Brown JT; Yantorni LB; Anne Russler G; Caulfield S; Joshi SS; Narayan VM; Kissick H; Ogan K; Master VA; Carthon BC; Kucuk O; Bilen MA
Oncologist; 2023 Dec; 28(12):1072-1078. PubMed ID: 37285524
[TBL] [Abstract][Full Text] [Related]
30. Impact of sex on the efficacy of immune checkpoint inhibitors in kidney and urothelial cancers: a systematic review and meta-analysis.
Yanagisawa T; Kawada T; Quhal F; Bekku K; Laukhtina E; Rajwa P; von Deimling M; Majdoub M; Chlosta M; Pradere B; Mori K; Kimura T; Schmidinger M; Karakiewicz PI; Shariat SF
World J Urol; 2023 Jul; 41(7):1763-1774. PubMed ID: 37209143
[TBL] [Abstract][Full Text] [Related]
31. Safety of COVID-19 vaccines in subjects with solid tumor cancers receiving immune checkpoint inhibitors.
Gilbert D; Hu J; Medina T; Kessler ER; Lam ET
Hum Vaccin Immunother; 2023 Dec; 19(1):2207438. PubMed ID: 37157982
[TBL] [Abstract][Full Text] [Related]
32. Immune Checkpoint Inhibitor-Associated Primary Adrenal Insufficiency: WHO VigiBase Report Analysis.
Grouthier V; Lebrun-Vignes B; Moey M; Johnson DB; Moslehi JJ; Salem JE; Bachelot A
Oncologist; 2020 Aug; 25(8):696-701. PubMed ID: 32390168
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of the Safety and Efficacy of Immunotherapy Rechallenge in Patients With Renal Cell Carcinoma.
Ravi P; Mantia C; Su C; Sorenson K; Elhag D; Rathi N; Bakouny Z; Agarwal N; Zakharia Y; Costello BA; McKay RR; Narayan V; Alva A; McGregor BA; Gao X; McDermott DF; Choueiri TK
JAMA Oncol; 2020 Oct; 6(10):1606-1610. PubMed ID: 32469396
[TBL] [Abstract][Full Text] [Related]
34. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
35. Hypophysitis induced by immune checkpoint inhibitors: a 10-year assessment.
Di Dalmazi G; Ippolito S; Lupi I; Caturegli P
Expert Rev Endocrinol Metab; 2019 Nov; 14(6):381-398. PubMed ID: 31842671
[No Abstract] [Full Text] [Related]
36. Safety and efficacy of immune checkpoint inhibitor cancer therapy in patients with preexisting type 1 diabetes mellitus.
Hilder R; Tsai K; Quandt Z; Isaacs D; Drakaki A; Xing Y; In GK; Angell TE; Lechner MG
Front Endocrinol (Lausanne); 2023; 14():1242830. PubMed ID: 38027216
[TBL] [Abstract][Full Text] [Related]
37. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
[TBL] [Abstract][Full Text] [Related]
38. Frontline immune checkpoint inhibitor-based combination therapy in metastatic renal cell carcinoma patients with poor performance status.
Carril-Ajuria L; Colomba E; Romero-Ferreiro C; Cerbone L; Ratta R; Barthelemy P; Vindry C; Fléchon A; Cherifi F; Boughalem E; Linassier C; Fornarini G; Rebuzzi SE; Gross-Goupil M; Saldana C; Martin-Soberón M; de Velasco G; Manneh R; Pernaut C; Sanchez de Torre A; Flippot R; Escudier B; Albiges L
Eur J Cancer; 2023 Feb; 180():21-29. PubMed ID: 36527973
[TBL] [Abstract][Full Text] [Related]
39. Incidence of Endocrine-Related Dysfunction in Patients Treated with New Immune Checkpoint Inhibitors: A Meta-Analysis and Comprehensive Review.
Yoo WS; Ku EJ; Lee EK; Ahn HY
Endocrinol Metab (Seoul); 2023 Dec; 38(6):750-759. PubMed ID: 37956967
[TBL] [Abstract][Full Text] [Related]
40. Immune-Related Adverse Events as Clinical Biomarkers in Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors.
Martini DJ; Goyal S; Liu Y; Evans ST; Olsen TA; Case K; Magod BL; Brown JT; Yantorni L; Russler GA; Caulfield S; Goldman JM; Nazha B; Harris WB; Kissick HT; Master VA; Kucuk O; Carthon BC; Bilen MA
Oncologist; 2021 Oct; 26(10):e1742-e1750. PubMed ID: 34156726
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]